These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31765498)

  • 1. Assessment of factors associated with completeness of spontaneous adverse event reporting in the United States: A comparison between consumer reports and healthcare professional reports.
    Toki T; Ono S
    J Clin Pharm Ther; 2020 Jun; 45(3):462-469. PubMed ID: 31765498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential completeness of spontaneous adverse event reports among hospitals/clinics, pharmacies, consumers, and pharmaceutical companies in South Korea.
    Oh IS; Baek YH; Kim HJ; Lee M; Shin JY
    PLoS One; 2019; 14(2):e0212336. PubMed ID: 30763386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
    Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
    Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
    Moore TJ; Furberg CD; Mattison DR; Cohen MR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):713-8. PubMed ID: 26861066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers.
    Christ P; Dubrall D; Schmid M; Sachs B
    Drug Saf; 2023 Dec; 46(12):1363-1379. PubMed ID: 37987966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and completeness of spontaneous reports by reporter's role in Germany: An analysis of the EudraVigilance database using the example of opioid-associated abuse, dependence, or withdrawal.
    Jobski K; Bantel C; Hoffmann F
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01077. PubMed ID: 36959713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database.
    Toki T; Ono S
    Drugs Real World Outcomes; 2018 Jun; 5(2):117-128. PubMed ID: 29725886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
    Aagaard L; Hallgreen CE; Hansen EH
    Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis.
    Araujo AGS; Lucchetta RC; Tonin FS; Pontarolo R; Borba HHL; Wiens A
    Expert Opin Drug Saf; 2021 Jun; 20(6):735-740. PubMed ID: 33641547
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria.
    Elemuwa UG; Bitrus F; Oreagba IA; Osakwe AI; Abiodun AS; Onu K; Abubakar A; Faniyi AE; Etuk V; Yuah D; Momodu R; Adeyeye CM
    Pharmaceut Med; 2024 May; 38(3):251-259. PubMed ID: 38705932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G; Salvo F; Moride Y
    Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis.
    Anzai T; Takahashi K; Watanabe M; Mochizuki M; Murashima A
    BMC Psychiatry; 2020 Mar; 20(1):118. PubMed ID: 32164630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
    Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
    Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
    Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
    Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.